Merck to buy insulin developer
Drugmaker Merck & Co. said it will buy insulin developer SmartCells in a deal that may exceed $500 million if development and regulatory milestones are met.
Merck & Co. said it achieved positive results in Phase 3 trials of its experimental insomnia treatment, a key drug in the pharmaceutical giant's pipeline.